<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026177</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-125-06</org_study_id>
    <nct_id>NCT05026177</nct_id>
  </id_info>
  <brief_title>Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease</brief_title>
  <acronym>REFOCUS-ALZ</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cassava Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research International LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cassava Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants&#xD;
      with mild-to-moderate Alzheimer's disease (AD) for 76 weeks. Approximately 1083 participants&#xD;
      will be randomized (1:1:1) to receive either placebo, 50 mg tablets of simufilam, or 100 mg&#xD;
      tablets of simufilam, twice daily, for 76 weeks. Clinic visits will occur 4 weeks after the&#xD;
      baseline visit, and then every 12 weeks until the end of the study. The safety of simufilam,&#xD;
      and its efficacy in enhancing cognition and slowing cognitive and functional decline will be&#xD;
      evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to investigate the safety and efficacy of simufilam&#xD;
      (PTI-125) in enhancing cognition and slowing cognitive and functional decline following&#xD;
      76-week, repeat-dose oral administration in participants with mild-to-moderate AD. Secondary&#xD;
      objectives are to assess neuropsychiatric symptoms and to replicate the cerebrospinal fluid&#xD;
      (CSF) biomarker effects observed in the two Phase 2 studies (PTI-125-03 and PTI-125-02) after&#xD;
      76 weeks of simufilam treatment. A third objective is to investigate the effect of simufilam&#xD;
      treatment on plasma biomarkers as well as anatomical correlates of disease progression (brain&#xD;
      volume [hippocampus, ventricles and whole brain]; and amyloid and tau deposition in the&#xD;
      brain). A limited number of research sites will be invited to participate in sub-studies to&#xD;
      assess the impact of simufilam on anatomical and biomarker endpoints, including: change from&#xD;
      baseline in CSF biomarkers (30 subjects/group); brain volume via magnetic resonance imaging&#xD;
      (MRI) (50 subjects/group); and amyloid and tau positron emission tomography (PET) (40 and 50&#xD;
      subjects/group, respectively). Participants in both PET sub-studies will provide plasma for a&#xD;
      biomarker sub-study, and those in the tau PET sub-study will also provide additional plasma&#xD;
      for a pharmacokinetic (PK) exposure response analysis. Changes from baseline for these&#xD;
      imaging and fluid biomarkers represent additional secondary endpoints. The 90 subjects (30&#xD;
      per group) in the CSF sub-study will undergo lumbar puncture during the Screening Period and&#xD;
      again at the Week 76 End-of-Treatment Visit to collect CSF biomarkers.&#xD;
&#xD;
      Safety will be evaluated by adverse event monitoring, vital signs, clinical labs, and the&#xD;
      Columbia Suicide Severity Rating Scale at every visit. All subjects will undergo magnetic&#xD;
      resonance imaging (MRI) during screening to ensure entry criteria are met, however, 150&#xD;
      subjects (50 subjects per treatment group) will also undergo repeat MRI assessments at Weeks&#xD;
      40 and 76 to assess both long-term safety and drug impact on brain volume as noted above.&#xD;
      Electrocardiograms will be conducted on Day 1 and Weeks 4, 40 and 76. A complete physical and&#xD;
      neurological examination will be performed at screening, and brief examinations will be&#xD;
      performed at all other visits. Weight will be measured during the Screening Period, on Study&#xD;
      Day 1 and at all other visits.&#xD;
&#xD;
      An independent Data Safety Monitoring Board (DSMB) will meet periodically to review subject&#xD;
      safety assessments and determine if dosing may continue. A charter will be developed with&#xD;
      specific guidance for the DSMB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized treatments will be assigned by subject numbers in a randomly generated numeric sequence. Randomization (1:1:1) will be stratified by low or high Mini-Mental State Exam (MMSE; 16-20 and 21-27).&#xD;
The randomization code will not be revealed to study subjects, Investigators, clinical staff, study monitors or the Sponsor until all subjects have completed therapy and the database has been finalized and locked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the ADAS-Cog12, a psychometrician-administered battery comprised of several cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Scores range from 0 (best) to 80 (worst).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the ADCS-ADL, a 23-item study partner questionnaire that covers both basic activities of daily living (ADL) and more complex ADL or instrumental ADL. Scores range from 0 to 78, with a lower score indicating greater severity of functional loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the integrated Alzheimer's Disease Rating Scale (iADRS)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the iADRS, where scores range from 0 to 146 with lower scores indicating worse performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the NPI, a 12-item study partner interview, which records the frequency and severity of common neuropsychiatric symptoms in dementia, as well as the level of study partner distress due to these neuropsychiatric problems. Scores range from 0 to 144, with higher scores indicating more frequent and severe symptoms, and greater levels of partner distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the MMSE</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the MMSE, a set of standardized questions covering several target areas: orientation, registration, attention and calculation, short-term verbal recall, naming, repetition, 3-step command, reading, writing, and visuospatial cognitive assessment. Lower sores indicate more severe impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Clinical Dementia Rating Sum of Boxes (CDR-SB)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the CDR-SB, which characterizes 6 domains of cognitive and functional performance applicable to AD and related dementias: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Higher scores indicate more severe impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Zarit Burden Interview (ZBI)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the ZBI, a 22-item study partner questionnaire designed to assess the stress or burden experienced by caregivers of people with dementia, with a higher score indicating greater stress or burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in CSF neurogranin, neurofilament light chain, total tau, phospho-tau181 (P-tau181), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and Aβ42</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>Changes from baseline in CSF biomarkers of AD pathology, neurodegeneration, and neuroinflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in brain volume via MRI</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>Changes from baseline in hippocampus, ventricles, and whole brain volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in amyloid and tau PET</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>Changes from baseline in amyloid and tau deposition in the brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in plasma biomarkers P-tau181 and neurofilament light chain</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>Change from baseline in plasma biomarkers of AD pathology and neurodegeneration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma biomarker SavaDx</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>SavaDx is a novel plasma biomarker</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1083</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 76 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simufilam 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simufilam 50 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simufilam 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simufilam</intervention_name>
    <description>Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.</description>
    <arm_group_label>Simufilam 100 mg</arm_group_label>
    <arm_group_label>Simufilam 50 mg</arm_group_label>
    <other_name>PTI-125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo given b.i.d. for 76 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Meets National Institute on Aging and Alzheimer's Association Research Framework&#xD;
             criteria for individuals in clinical Stage 4 or 5 of the Alzheimer's continuum.&#xD;
&#xD;
          2. Evidence for AD pathophysiology, confirmed prior to screening&#xD;
&#xD;
          3. MMSE score ≥ 16 and ≤ 27 at screening.&#xD;
&#xD;
          4. Clinical Dementia Rating - Global Score must be 0.5, 1 or 2.&#xD;
&#xD;
          5. If receiving background AD medications, the dosing regimen must be stable for at least&#xD;
             12 weeks prior to randomization.&#xD;
&#xD;
          6. The subject has been a non-smoker for at least 3 years.&#xD;
&#xD;
          7. Availability of a study partner&#xD;
&#xD;
          8. Individuals who have participated in a clinical study with an investigational drug&#xD;
             targeting the underlying AD process may be permitted to participate in this study.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. A neurologic condition other than AD that significantly contributes to the subject's&#xD;
             dementia.&#xD;
&#xD;
          2. Any current primary psychiatric diagnosis other than AD if it is likely to confound&#xD;
             cognitive assessment or ability to comply with study procedures&#xD;
&#xD;
          3. Geriatric Depression Scale (15-item) score &gt; 8&#xD;
&#xD;
          4. Suicidal ideation during the past 3 months or suicidal behavior during the past 12&#xD;
             months&#xD;
&#xD;
          5. Alcohol or substance use disorder within 2 years of screening&#xD;
&#xD;
          6. MRI presence of cerebral vascular or other significant pathology&#xD;
&#xD;
          7. History of transient ischemic attack or stroke within 12 months of screening&#xD;
&#xD;
          8. Seizure within 12 months of screening.&#xD;
&#xD;
          9. Severe head trauma or head trauma considered likely to be contributing to the&#xD;
             subject's cognitive impairment.&#xD;
&#xD;
         10. Sleep apnea that is considered likely to be contributing to the subject's cognitive&#xD;
             impairment.&#xD;
&#xD;
         11. Insufficiently controlled diabetes mellitus or hypertension&#xD;
&#xD;
         12. Body mass index &lt; 18.5 or &gt; 35.0.&#xD;
&#xD;
         13. History or diagnosis of clinically significant cardiac disease&#xD;
&#xD;
         14. Prescribed aducanumab.&#xD;
&#xD;
         15. COVID-19 infection within 3 months of screening. If no history of a prior COVID-19&#xD;
             infection, subject must be fully vaccinated for COVID-19 at least 2 weeks prior to&#xD;
             randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Kupiec, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cassava Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carrie Crowley</last_name>
    <phone>512-501-2453</phone>
    <email>ccrowley@cassavasciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracy Owen</last_name>
    <phone>512-501-3178</phone>
    <email>towen@cassavasciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neurology Center of North Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Johnson Moon, MD</last_name>
      <phone>714-879-7200</phone>
      <email>johnson.l.moon@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sheraz Mossa</last_name>
      <phone>714-879-7200</phone>
      <email>smossa1@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Johnson Moon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark Goldstein, MD</last_name>
      <phone>561-968-2933</phone>
      <email>mgoldstein@jemri.net</email>
    </contact>
    <contact_backup>
      <last_name>McKenzie Lang</last_name>
      <email>mckenzie.lang@headlandsresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research Inc</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark Brody, MD</last_name>
      <phone>561-374-8461</phone>
      <email>mbrody@brainmattersresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Ana Fuquay</last_name>
      <phone>561-374-8461</phone>
      <phone_ext>1031</phone_ext>
      <email>afuquay@ergclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Brody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Evelio Sosa, MD</last_name>
      <phone>305-825-6588</phone>
      <email>esosa@indagoresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Diana Fagundo</last_name>
      <phone>305-825-6588</phone>
      <email>BusinessDevelopment@indagoresearch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Evelio Sosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gonzalez MD &amp; Aswad MD Healthcare Services / Optimus U</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Yaneicy Gonzalez Rojas, MD</last_name>
      <phone>305-240-5206</phone>
      <email>drgonzalez@optimusu.com</email>
    </contact>
    <investigator>
      <last_name>Yaneicy Gonzalez Rojas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intercoastal Medical Group - Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mauricio Concha, MD</last_name>
      <phone>941-906-7155</phone>
      <email>mconcha@intercoastalmedical.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeanette Wilson</last_name>
      <phone>941-906-7155</phone>
      <email>JeWilson@intercoastalmedical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mauricio Concha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research &amp; Treatment Center</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Watson, MD</last_name>
      <phone>561-209-2400</phone>
      <email>dwatson@researchalz.com</email>
    </contact>
    <investigator>
      <last_name>David Watson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Memory Center, PC</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonathan Liss, MD</last_name>
      <phone>706-327-4000</phone>
      <email>jliss@lissmd.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Liss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroStudies</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marshall Nash, MD</last_name>
      <phone>404-475-0552</phone>
      <email>mnash@accelclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Chelsea Cornelison</last_name>
      <phone>386-740-0770</phone>
      <phone_ext>343</phone_ext>
      <email>ccornelison@accelclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marshall Nash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Global Medical Institutes, LLC</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeffrey Apter, MD</last_name>
      <phone>609-921-3555</phone>
      <email>jtapter@gminstitutes.com</email>
    </contact>
    <contact_backup>
      <last_name>Roma Kotak</last_name>
      <phone>(609) 921-3555</phone>
      <phone_ext>109</phone_ext>
      <email>regulatory@gminstitutes.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Apter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of New Jersey (CRCNJ)</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michelle Papka, MD</last_name>
      <phone>973-850-4622</phone>
      <email>mpapka@thecrcnj.com</email>
    </contact>
    <investigator>
      <last_name>Michelle Papka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute of NJ</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sanjiv Sharma, MD</last_name>
      <phone>732-341-9500</phone>
      <email>ssharma@amrinj.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna Brocco</last_name>
      <phone>732-341-9500</phone>
      <email>abrocco@amrinj.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjiv Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists of Monmouth County</name>
      <address>
        <city>West Long Branch</city>
        <state>New Jersey</state>
        <zip>07764</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Noah Gilson, MD</last_name>
      <phone>732-935-1850</phone>
      <email>ngmdresearch@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Avraham Tuvy</last_name>
      <phone>732-935-1850</phone>
      <email>avtuvy@neurologyspecialists.org</email>
    </contact_backup>
    <investigator>
      <last_name>Noah Gilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Richard Holub, MD</last_name>
      <phone>518-426-0575</phone>
      <email>rholub@naaresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Mary Ellen</last_name>
      <email>Research@naaresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Holub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joan Rothenberg, MD</last_name>
      <email>jrothenberg@velocityclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Kate Fargus</last_name>
      <phone>216-682-0320</phone>
      <phone_ext>240</phone_ext>
      <email>kfargus@velocityclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joan Rothenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research, Inc.</name>
      <address>
        <city>North Canton</city>
        <state>Ohio</state>
        <zip>44720</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shishuka Malhotra, MD</last_name>
      <email>smalhotra@nb-cr.com</email>
    </contact>
    <investigator>
      <last_name>Shishuka Malhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marvin Kalafer, MD</last_name>
      <phone>215-884-1700</phone>
      <email>drkalafer@theclinicaltrialcenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Alketa Dobi</last_name>
      <phone>215-884-1700</phone>
      <email>alketa@theclinicaltrialcenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marvin Kalafer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keystone Clinical Studies, LLC</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Cherian Verghese, MD</last_name>
      <phone>610-277-8073</phone>
      <email>cherian.verghese@keystoneclinicalstudies.com</email>
    </contact>
    <investigator>
      <last_name>Cherian Verghese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Consultants of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Duc Tran, MD</last_name>
      <email>dtran@neurologydallas.com</email>
    </contact>
    <contact_backup>
      <email>research@neurologydallas.com</email>
    </contact_backup>
    <investigator>
      <last_name>Duc Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Malgorzata Franczak, MD</last_name>
      <phone>414-955-0650</phone>
      <email>mfranczak@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Blaney</last_name>
      <phone>414-955-0609</phone>
      <email>bblaney@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Malgorzata Franczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OCT Research ULC DBA Okanagan Clinical Trials</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 2Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Eugene Okorie, MD</last_name>
      <phone>250-862-8141</phone>
    </contact>
    <contact_backup>
      <last_name>Kim Christie, MD</last_name>
      <phone>250-862-8141</phone>
      <email>drchristie@oktrials.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Eugene Okorie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Memory Clinic</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Z 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Richard Bergeron, MD</last_name>
      <phone>613-702-1000</phone>
      <email>rbergeron@cliniquememoire.ca</email>
    </contact>
    <contact_backup>
      <last_name>Elitza Hristova</last_name>
      <phone>613-702-1000</phone>
      <phone_ext>415</phone_ext>
      <email>ehristova@cliniquememoire.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Bergeron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Recherches Neuro-Hippocampe Inc.</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8T 8J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Richard Bergeron, MD</last_name>
      <phone>819-510-1000</phone>
      <email>rbergeron@cliniquememoire.ca</email>
    </contact>
    <contact_backup>
      <last_name>Marielle Thibeault</last_name>
      <phone>819-510-1000</phone>
      <phone_ext>235</phone_ext>
      <email>mthibeault@cliniquememoire.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Bergeron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

